Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Solid Tumor, Adult 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1

Interventions

Nivolumab 6Imatinib Mesylate 4Ipilimumab 3Cetuximab 3pembrolizumab 2palbociclib 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Protons 2Proton Therapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tazemetostat 1spartalizumab 1relatlimab 1nilotinib 1camrelizumab 1avelumab 1atezolizumab 1apatinib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Thiotepa 1Radiotherapy, Intensity-Modulated 1Radiation 1Photochemotherapy 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chordoma × Tiragolumab × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡